Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | EIF4E | P06730 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594177 | 0.83 | IDO1 (0.57) | TP53MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL29979724 | 0.81 | APP (0.54) | BACE1CYP2C8KIF11PSEN1PSEN2 | |
| SCHEMBL23354220 | 0.81 | APP (0.54) | BACE1CYP2C8KIF11PSEN1PSEN2 | |
| Xenalipin SCHEMBL29881739 | 0.80 | CYP2C8 (0.58) | BACE1CYP2C8KIF11TP53POLB | |
| Xenalipin SCHEMBL133087 | 0.80 | CYP2C8 (0.58) | BACE1CYP2C8KIF11TP53POLB | |
| SCHEMBL23354157 | 0.80 | KDM4E (0.59) | BACE1CYP2C8ACLYPSEN1PSEN2 | |
| SCHEMBL6799953 | 0.79 | RXRA (0.55) | BACE1CYP2C8ACLYPSEN1PSEN2 | |
| SCHEMBL421844 | 0.79 | ALDH1A1 (0.57) | BACE1CYP2C8KIF11GRIK1ACLY | |
| SCHEMBL343208 | 0.79 | HSD17B10 (0.53) | BACE1CYP2C8KIF11KDM4EALDH1A1 | |
| Xenalipin SCHEMBL3723586 | 0.79 | CYP2C8 (0.56) | BACE1CYP2C8KIF11TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114993-B2 | Use of aryl chlorides in palladium-catalyzed C-H bond functionalization | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | DBH, DDT, CYCS | BACE1 4452/4885CYP2C8 77/4885KIF11 2377/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | BACE1 49/4885CYP2C8 710/4885KIF11 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.